TO THE EDITOR: Dörffel et al1 recently reported results from the nonrandomized phase II
German Society of Pediatric Oncology and Hematology–Hodgkin's Disease 95 (GPOH …

Radiation is commonly used as a treatment intended to cure or palliate cancer patients.
Despite remarkable advances in the precision of radiotherapy delivery, even the most …

A substantial fraction of patients demonstrate resistance to immune checkpoint inhibitors,
which limits their use. Use of radiation concurrently with checkpoint inhibitors has been …

Pediatric Hodgkin lymphoma (PHL) remains one of the great medical success stories of the
last century whereby a previously incurable malignancy is now cured in more than 85% of …

(1) Background: Radiation-induced sarcomas (RIS) are rare diseases with poor prognoses.
The aim of the study was to analyze outcomes and identify factors affecting survival in a …

Programmed death-1 (PD-1) checkpoint inhibitors have shown promising results for the
treatment of various tumor types, including relapsed and refractory Hodgkin's lymphoma …

The paradigm of response in Hodgkin lymphoma (HL) was developed in cytotoxic
chemotherapies and its use as a reference model for immune-modulatory regimens, which …

Glioblastoma multiforme is the most frequent primary brain tumor. The clinical course of
glioblastoma is almost invariably fatal. Combined chemo-irradiation with temozolomide is …

The programmed death-1 (PD-1) regulatory pathway is active in several tumors and a potent
immunotherapeutic target with PD-1 inhibitors. Nivolumab is an anti-PD-1 monoclonal …